At some point in the natural history of hypertension,
|
|
- Amie Nichols
- 5 years ago
- Views:
Transcription
1 Evaluation of Subclinical Target Organ Damage for Risk Assessment and Treatment in the Hypertensive Patients: Left Ventricular Hypertrophy Enrico Agabiti-Rosei, Maria Lorenza Muiesan, and Massimo Salvetti Internal Medicine, University of Brescia, Brescia, Italy At some point in the natural history of hypertension, the compensatory increase in left ventricular mass ceases to be beneficial. Left ventricular hypertrophy (LVH) becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemic heart disease, arrhythmia, sudden death, and stroke. In addition to elevated BP, several mechanisms are involved, including body size, age, gender, race, fibrogenic cytokines, and neurohumoral factors, notably angiotensin II, which favor interstitial collagen deposition and perivascular fibrosis. These tissue changes are responsible for the insidious contractile dysfunction that is associated with LVH, consequent to decreased coronary reserve and altered diastolic ventricular filling and relaxation. The cardinal investigations are echocardiography and electrocardiography. All antihypertensive drugs regress LVH, notably those that act on the renin-angiotensin-aldosterone system, which also could target the detrimental tissue changes. Regression enhances systolic midwall performance, normalizes autonomic function, and restores coronary reserve. The resulting improvement in prognosis has enshrined the detection, prevention, and reversal of LVH in the current guidelines of hypertension management. J Am Soc Nephrol 17: S104 S108, doi: /ASN At some point in the natural history of hypertension, the compensatory increase in left ventricular mass (LVM) is not beneficial anymore. In fact, it becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemic heart disease, arrhythmia, sudden death, and stroke (1). Determinants of Hypertensive Left Ventricular Hypertrophy The high prevalence of LV hypertrophy (LVH) in hypertension reflects the increased afterload imposed on the left ventricle, although other important determinants are demographic characteristics (e.g., age, gender, race), neurohumoral and growth factors, and underlying genetic factors. Hypertension is the fundamental trigger to the sequence of biologic events that lead to the development of LVH. LVM is more closely related to average 24-h BP (2 4). Volume load, inotropy, and arterial compliance also are important determinants of the development and the degree of LVH. Other contributing factors include stage of hypertensive disease, genetics, demographic factors, comorbid diseases (e.g., diabetes, obesity, coronary artery disease), possibly mediated via cardiac load. Obesity, which compounds hemodynamic load independent of a clear-cut increase in BP, is a major determinant of LVM, because it is associated with increased plasma volume and cardiac output (5). It has been suggested that considering these measurable factors and Address correspondence to: Prof. Enrico Agabiti-Rosei, Internal Medicine, Medical and Surgical Sciences, University of Brescia, c/o 2a Medicina Spedali Civili di Brescia, Piazza Spedali Civili 1, Brescia, Italy. Phone: ; Fax: ; agabiti@med.unibs.it hemodynamic load, echocardiographic LVM could be assessed in the individual patient as deviation from the value that is appropriate for a given cardiac workload, corrected for gender and body size. LVM that overcompensates for hemodynamic load tends to cluster with metabolic risk factors and is associated with high cardiovascular risk (6,7). The definition and the clinical evaluation of inappropriate LVM require further study. Among the main nonhemodynamic factors that may contribute to the development of LVH, a variety of neurohumoral and growth factors (e.g., catecholamines, angiotensin II [AngII], aldosterone, endothelins) are included. The effect of sympathetic nervous system activity is evident in experimental models but less clear-cut in humans: in pheochromocytoma LVH prevalence is relatively low and LVM seems to increase proportionately to BP, then in essential hypertension, LVH is associated with altered autonomic activity and a blunted response to -adrenoceptor stimulation (8 10). Experimental studies also highlighted the role of the renin-angiotensin-aldosterone system (RAAS) in mediating LVH (11,12). AngII induces hypertrophy and hyperplasia in myocytes and vascular smooth muscle cells and may regulate collagen synthesis. Excess AngII production may regulate the expression of fibrogenic cytokine TGF- 1 and favor perivascular and interstitial fibrosis. In addition, AngII may interfere with the process of collagen degradation, modulating the activity of metalloproteinases (a family of zinc-containing proteins that include stromelysins, collagenases, and gelatinases) and their inhibitors (12). Aldosterone also may stimulate extracellular collagen deposition and myocardial fibrosis. The pathogenic role of the RAAS in the development of Copyright 2006 by the American Society of Nephrology ISSN: /
2 J Am Soc Nephrol 17: S104 S108, 2006 Pathophysiology and Treatment of Hypertensive LVH S105 hypertensive LVH requires confirmation, although LVM is significantly increased in renovascular hypertension and primary aldosteronism compared with essential hypertension (13,14). Increased activity of the RAAS and sympathetic nervous system, hypervolemia, and anemia all may influence the increase of LVM in patients with renal disease. Hypertensive LVH often is associated with insulin resistance and high insulin levels (15). The involvement of IGF- I could clarify the link among obesity, BP elevation, LVH, and the metabolic syndrome. Leptin is another possible neuroendocrine determinant. LVH in an animal model of leptin deficiency (the ob/ob mouse) reversed rapidly in response to exogenous leptin, therefore indicating the involvement of myocardial leptin receptors in cardiac remodeling (16). Other major metabolic cardiovascular risk factors, notably hypercholesterolemia and hyperglycemia, also may have an influence on LVM and the prevalence of LVH (17). Several studies have suggested that approximately 30% of LVM variance is genetically determined (18). Studies of genetic influence on LVM have focused mainly and are ongoing on the role of candidate genes, including those that are related to the RAAS, - and -adrenoceptors, and components of the signal transduction mechanisms involved in cardiac hypertrophy. Methods of Assessing LVH As recommended by the European Society of Hypertension and European Society of Cardiology (19), LVH is diagnosed most commonly using electrocardiography (ECG) and M-mode and two-dimensional echocardiography. New ECG criteria in addition to repolarization abnormalities and increased voltage have been proposed, the Cornell method probably being the most sensitive (20). The ECG also can be used to detect patterns of ventricular overload ( strain ) or ischemia, which indicate higher cardiovascular risk. ECG and echocardiographic LVH both predict mortality independent of each other and other cardiovascular risk factors, thus conveying, at least in part, different prognostic information (21,22). Echocardiography has some advantages because it provides comprehensive wall, chamber, and LVM measures, together with systolic and diastolic performance indices, while remaining reasonably cheap, widely available, and wholly noninvasive. The relation between LVM and cardiovascular risk is continuous, although the threshold of 125 g/m 2 for men and 110 g/m 2 for women currently is used most widely for conservative estimates of LVH, according to the recent European Society of Hypertension European Society of Cardiology guidelines (19). Despite its advantages, echocardiography may entail a possible technical error as a result of the method itself, the quality of the examination, or observer inexperience. It has been established that a biologic significance can be attributed to changes in LVM that exceed 10 to 15% (23). Echocardiography also is useful in assessing the different types of LV geometric adaptation to increased cardiac load (24), evaluating the increase in mass and/or in relative wall thickness. More accurate and sophisticated techniques, such as magnetic resonance imaging or cine computerized tomography, are more expensive or time-consuming and are still of limited availability. Methods have been developed to quantify tissue composition. Studies in animals and humans have shown that LV acoustic properties under physiologic and pathologic conditions are influenced by several tissue components (myocardium, contractile and elastic tissue, collagen and inelastic tissue, arteries, veins, myocytes, and sarcomeres). Results with videodensitometry and integrated backscatter to characterize tissue in several diseases that are associated with abnormal myocardial tissue, including hypertensive LVH and diabetes, indicate that these techniques can complement clinical evaluation by revealing preclinical end-organ damage (25,26). Further reproducibility and feasibility studies are required to assess the clinical applications of these techniques. Prognostic Significance of LVH Whether assessed by ECG or echocardiography, LVH is a well-documented harbinger of morbidity and mortality. In several studies, the adjusted risk for cardiovascular morbidity associated with baseline LVH ranges from 1.5 to 3.5 with a weighted risk ratio of 2.3 for all studies combined (27). Concentric hypertrophy seems to carry the highest risk and eccentric hypertrophy an intermediate risk, whereas concentric remodeling is probably associated with a smaller, albeit noteworthy, risk. The structural remodeling of cardiomyocytes, nonmyocytes, and fibroblasts that occurs in cardiac hypertrophy contributes to perivascular fibrosis, initially around intramural coronary arteries and thereafter in the interstitial space, leading to progressive abnormalities of diastolic ventricular filling and relaxation, systolic dysfunction, arrhythmias, and conduction disturbances, thereby greatly compounding the risk that is associated with LVH (1). The resulting pathophysiologic and clinical changes that account for increased risk in hypertensive LVH include both diastolic and systolic dysfunction. LVH and failure are frequently associated with coronary artery disease, and hypertension is a major risk factor for coronary atherosclerosis. In ECG LVH, use of a definite LVH pattern that comprises ST-segment and T-wave abnormalities was strongly associated with an increased incidence of acute myocardial infarction and sudden death (3 6), suggesting that altered repolarization reflects reduced coronary perfusion. LVH is associated with structural and functional changes in both large (28,29) and small (14,30,31) arteries. These structural changes are particularly evident in concentric LVH. The association between LVH and extracranial carotid atherosclerosis also might explain the increased risk for cerebrovascular events. The vascular changes that consistently are observed in LVH are also responsible for the reduced coronary reserve. Concomitant atherosclerosis in epicardial coronary vessels and structural alterations and rarefaction of small coronary vessels (32) limit blood supply when oxygen demand is increased. Compensatory angiogenesis is inadequate during the development of adult LVH. Decreased subendocardial coronary perfusion leads to myocyte necrosis and reparative fibrosis, favoring
3 S106 Journal of the American Society of Nephrology J Am Soc Nephrol 17: S104 S108, 2006 the progression to heart failure. Other extravascular mechanisms that compound the impairment of coronary reserve include changes of oxygen demand related to wall tension, heart rate, and contractility. Functional changes further weaken the vasodilator response of the coronary microcirculation. In fact, endothelial dysfunction precedes morphologic changes in the vascular wall and triggers remodeling. In summary, LVH is a state of potential or actual myocardial ischemia. There is a predisposition to ventricular arrhythmia in hypertensive LVH, explaining the risk for sudden death. Impaired ventricular filling, left atrial enlargement, and slowing of atrial conduction velocity all encourage atrial fibrillation, increasing the risk for thromboembolism. In addition, in patients with LVH (and abnormal LV geometry), higher urinary albumin excretion has been observed, suggesting that cardiac and glomerular vascular damage may parallel, independent of the hemodynamic load. Because hypertensive LVH is an independent risk factor for cardiovascular morbidity and mortality, the possibility of reversal or even prevention by lowering BP and modifying other pathogenetic factors is a major goal of antihypertensive therapy. LVH Regression by Antihypertensive Treatment LVM can be decreased by nonpharmacologic intervention, notably weight loss, which is effective in obese hypertensive patients independent of BP changes. As shown by the multicenter Treatment of Mild Hypertension Study (TOMHS), lifestyle intervention may reduce BP significantly and decrease LVM substantially in 30% of patients. However, there is still no hard evidence of an independent effect by dynamic exercise, dietary sodium, or alcohol restriction. Multiple studies have shown that BP reduction reverses LVH. The main determinants are treatment duration and degree of BP reduction, in particular of average 24-h BP; subsequent evidence also has shown the importance of homogeneity, or minimal daily fluctuation, in BP control, as expressed in the smoothness index (33,34). Because BP is not the sole determinant of LVH and fibrosis, the differing response of LVM to various classes of antihypertensive drugs can be ascribed to interference with nonhemodynamic factors such as the RAAS and sympathetic nervous system. Several meta-analyses have been conducted, including the main studies demonstrating reversal of echocardiographic LVH using various antihypertensive drugs, and they have shown that baseline LVM and the degree of BP reduction are the main determinants of LVH regression; in addition angiotensin-converting enzyme inhibitors, AngII receptor blockers, and calcium channel blockers have been more effective than blockers and diuretics given the same decrease in BP (35). Large, randomized, blinded studies that have compared two or more different antihypertensive drugs have provided further data, confirming, at least in large part, the results of metaanalyses. However, it should be kept in mind that interdrug differences tend to fade with time, because treatment duration is associated with progressive BP control and decrease in LVM. In addition, most major intervention trials that have compared the effects of single antihypertensive drugs on LVM in fact largely have been comparisons of combination therapies, because most patients were taking more than one drug. There is increasing interest in the effect of antihypertensive treatment on myocardial tissue composition, particularly on perivascular and interstitial fibrous tissue. Recent experimental and human evidence suggests that angiotensin-converting enzyme inhibitors and AngII antagonists are particularly effective in inducing regression of myocardial fibrosis. Clinical and Prognostic Significance of LVH Regression Because LVH is such an important independent risk factor in hypertension, there is consensus as to the desirability of its regression and prevention. Regression is associated with numerous benefits, such as improved systolic midwall performance, normalized autonomic function, enhanced coronary reserve, and, possibly, improved diastolic filling and decreased ventricular arrhythmia. It remains to be assessed extensively whether LVM changes may improve parallel vascular and/or renal damage modifications. The improved prognosis associated with LVH regression has been demonstrated in several studies using ECG measures. The large long-term Losartan Intervention for Endpoint (LIFE) study showed that the greater regression of LVH with losartan was associated with fewer cardiovascular events (36). Further observations using the more sensitive echocardiographic technique have shown that patients who achieve LVH regression during follow-up are much less likely to experience morbid events as compared with those with persistence of LVH (odds ratio 0.41) (37). In the echocardiographic substudy of the LIFE trial that included 960 patients who were followed for 4 yr, the better prognosis that was associated with the significant decrease in LVM from baseline to end of study was due mainly to a decrease in the incidence of stroke (38). These cumulative findings highlight the prognostic value of the LVM response to treatment. BP was not significantly associated with the incidence of cardiovascular events in these studies, although it cannot be excluded that the changes that were observed in the LVM index at least partially reflected BP control. Whereas complete regression significantly reduces cardiovascular risk, an increase in echocardiographic LVM during antihypertensive therapy or a failure to decrease confers a worse prognosis. In addition, the response of LV geometry to treatment may have prognostic significance, independent of changes of LVM (39). Future Goals Focuses of future interest will include the biochemistry of the adaptive changes in energy metabolism and contractile proteins, notably the role of transmitters and transductional factors, as well as the timing of these responses to BP changes, neurohumoral activation, and the development of structural alterations in other organs. Techniques such as tissue characterization and noninvasive quantitative analysis of coronary
4 J Am Soc Nephrol 17: S104 S108, 2006 Pathophysiology and Treatment of Hypertensive LVH S107 flow will describe the respective contributions of perivascular and intraventricular fibrosis and myocardial ischemia to the mechanisms of LVH risk and, hopefully, indicate ways in which these advances can be translated into the individual patient benefit. However, we already know more than enough to realize that a major goal in the management of hypertension is the detection, prevention, and reversal of LVH. References 1. Frohlich ED: Risk mechanisms in hypertensive heart disease. Hypertension 34: , Parati G, Pomidossi G, Albini E, Malaspina D, Mancia G: Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 5: 93 98, Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, Porcellati C: Circadian blood pressure change and left ventricular hypertrophy in essential hypertension. Circulation 81: , Rizzoni D, Muiesan ML, Montani G, Zulli R, Calebich S, Agabiti-Rosei E: Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens 5: , de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH: Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 23: , de Simone G, Palmieri V, Koren M, Mensah G, Roman MJ, Devereux RB: Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens 19: , Palmieri V, Wachtell K, Gerdts E, Bella JN, Papademetriou V, Tuxen C, Nieminen MS, Dahlof B, de Simone G, Devereux RB: Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE study. Am Heart J 141: , Grassi G, Gianattasio C, Cleroux J, Cuspidi C, Sampieri L, Mancia G: Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension 12: , Rizzoni D, Agabiti-Rosei E, Castellano M, Beschi M, Montani G, Pizzocolo G, Poiesi C, Rodella A, Agabiti-Rosei E: Antidiuretic hormone and atrial natriuretic peptide during lower body negative or positive pressure in hypertensive patients with and without left ventricular hypertrophy. Clin Exp Hypertens A 14: , Trimarco B, De Luca N, Ricciardelli B, Rosiello G, Volpe M, Condorelli G, Lembo G, Condorelli M: Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol 62: , Schlaich MP, Schobel HP, Hilgers K, Schmieder RE: Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 85: , Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: , Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, Tiberio G, Giulini SM, Monteduro C, Garavelli G, Agabiti-Rosei E: Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32: , Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC: Remodeling of the left ventricle in primary aldosteronism due to Conn s adenoma. Circulation 195: , Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, Santeusanio F, Porcellati C, Brunetti P: Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 100: , Barouch LA, Berkowitz DE, Harrison RW, O Donnell CP, Hare JM: Disruption of lectin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108: , Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, Leonetti G, Magrini F, Zanchetti A: Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 22: , Post W, Larson M, Myers RH, Galderisi M, Levy D: Heritability of left ventricular mass. Hypertension 30: , Guidelines Committee: 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: , Devereux RB, Roman MJ: Evaluation of cardiac and vascular structure and function by echocardiography and other non-invasive techniques. In: Hypertension: Pathophysiology, Diagnosis and Management, New York, Raven Press, 1995, pp Sundstrom J, Lind L, Arnlov J, Zethelius B, Andren B, Lithell HO: Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 103: , Okin P, Roman MJ, Lee ET, Galloway JM, Howard B, Devereux RB: Combined echocardiographic left ventricular hypertrophy and electrocardiographic ST depression improve prediction of mortality in American Indians. The Strong Heart Study. Hypertension 43: , de Simone G, Muiesan ML, Ganau A, Longhini C, Verdecchia P, Palmieri V, Agabiti-Rosei E, Mancia G: Reliability and limitations of measurement of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: The RES trial. Working Group on Heart and Hypertension of the Italian Society of Hypertension. Reliability of M-mode Echocardiographic Studies. J Hypertens 17: , Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH: Patterns of left ventricular hypertrophy and geometric remodeling in arterial hypertension. J Am Coll Cardiol 19: , Di Bello V, Pedrinelli R, Giorgi D, Bertini A, Talarico L, Caputo MT, Massimiliano B, Dell Omo G, Paterni M, Giusti C: Ultrasonic videodensitometric analysis of two different models of left ventricular hypertrophy: Athlete s heart and hypertension. Hypertension 29: , Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F, Weber KT: Echocardiographic patterns of myo-
5 S108 Journal of the American Society of Nephrology J Am Soc Nephrol 17: S104 S108, 2006 cardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization. JAmSoc Echocardiogr 10: , Vakili B, Okin P, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J 141: , Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB: Association of carotid atherosclerotic and left ventricular hypertrophy. J Am Coll Cardiol 25: 83 90, Muiesan ML, Pasini G, Salvetti M, Calebich S, Zulli R, Castellano M, Rizzoni D, Bettoni G, Cinelli A, Porteri E, Corsetti V, Agabiti-Rosei E: Cardiac and vascular structural changes: Prevalence and relation to ambulatory blood pressure in a middle-aged general population in Northern Italy. The Vobarno Study. Hypertension 27: , Lucarini AR, Spessot M, Picano E, Marini C, Lattanzi F, Pedrinelli R, Salvetti A: Lack of correlation between cardiac mass and arteriolar structural changes in mild-tomoderate hypertension. J Hypertens 9: , Niteberg A, Anthony I: Epicardial coronary arteries are not adequately sized in hypertensive patients. J Am Coll Cardiol 27: , Rizzoni D, Palombo C, Porteri E, Muiesan ML, Kozakova M, La Canna G, Nardi M, Guelfi D, Salvetti M, Morizzo C, Vittone F, Rosei EA: Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J Hypertens 21: , Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatmentinduced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 95: , Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G: The smoothness index: A new reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 16: , Klingbeil A, Schneider M, Martus P, Messerli F, Schmieder R: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115: 41 46, Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B; Losartan Intervention for Endpoint reduction in hypertension Study Investigations: Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension. (LIFE) Study. Circulation 108: , Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E: Association of change in left ventricular mass with prognosis during longterm antihypertensive treatment. J Hypertens 13: , Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B: Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292: , Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E: Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 43: 1 8, 2004
HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY
2017, 18, nr. 66 HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY Enrico Agabiti Rosei, Maria Lorenza Muiesan Clinica Medica- Division of Internal Medicine, University Hospital, Brescia, Italy. In hypertension,
More informationRegression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study Peter M. Okin, MD; Richard B. Devereux,
More informationDoes the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy?
(24) 18, S23 S28 & 24 Nature Publishing Group All rights reserved 95-92/4 $3. www.nature.com/jhh ORIGINAL ARTICLE Does the reduction in systolic blood pressure alone explain the regression of left ventricular
More informationImpact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study)
European Journal of Echocardiography (2008) 9, 809 815 doi:10.1093/ejechocard/jen155 Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE
More informationHypertensive heart disease: left ventricular hypertrophy
Invited review Hypertensive heart disease: left ventricular hypertrophy Kristian Wachtell Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark Submitted: 13 February 2009 Accepted:
More informationLeft Ventricular Hypertrophy the Problem and Possible Solutions
The Journal of International Medical Research 2005; 33 (Suppl 1): 3A 11A Left Ventricular Hypertrophy the Problem and Possible Solutions P GOSSE Cardiology Service Arterial Hypertension, Hospital Saint-André,
More informationLeft Ventricular Structural and Functional Characteristics in Cushing s Syndrome
Journal of the American College of Cardiology Vol. 41, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00493-5
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationDIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING
DIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING Sh Narooei (1), B Soroor (2), F Zaker (3) Abstract INTRODUCTION: Hypertension is a very common cardiovascular
More informationGender-Adjustment and Cutoff Values of Cornell Product in Hypertensive Japanese Patients
CLINICAL STUDY Gender-Adjustment and Cutoff Values of Cornell Product in Hypertensive Japanese Patients Joji Ishikawa, 1 MD, Yuko Yamanaka, 2 MD, Ayumi Toba, 1 MD, Shintaro Watanabe, 3 MD and Kazumasa
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationAFRICA CARDIOVASCULAR JOURNAL OF AFRICA Vol 23, No 3, April 2012
AFRICA CARDIOVASCULAR JOURNAL OF AFRICA Vol 23, No 3, April 2012 147 Prevalence of residual left ventricular structural changes after one year of antihypertensive treatment in patients of African descent:
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationIn Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison
In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality
More informationDanno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?
Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia Percieved risk Actual risk Sehestedt et al,
More informationThe hypothesis that left ventricular hypertrophy (LVH) Regression of Left Ventricular Hypertrophy and Prevention of Stroke in Hypertensive Subjects
AJH 2006; 19:493 499 Heart Regression of Left Ventricular Hypertrophy and Prevention of Stroke in Hypertensive Subjects Paolo Verdecchia, Fabio Angeli, Roberto Gattobigio, Mariagrazia Sardone, Sergio Pede,
More informationAngiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension*
The Journal of International Medical Research 2005; 33 (Suppl 1): 21A 29A Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with
More informationImpact of Echocardiographic Left Ventricular Geometry on Clinical Prognosis
Accepted Manuscript Impact of Echocardiographic Left Ventricular Geometry on Clinical Prognosis Carl J. Lavie, Dharmendrakumar A. Patel, Richard V. Milani, Hector O. Ventura, Sangeeta Shah, Yvonne Gilliland
More informationNight time blood pressure and cardiovascular structure in a middle-aged general population in northern Italy: the Vobarno Study
(2001) 15, 879 885 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Night time blood pressure and cardiovascular structure in a middle-aged general
More informationTHE HEART AND HYPERTENSION. Philippe Gosse Hypertension Unit University Hospital Bordeaux
THE HEART AND HYPERTENSION Philippe Gosse Hypertension Unit University Hospital Bordeaux INCREASED LVM Cardiomyocytes hypertrophy is a response to pressure overload This response is influenced by many
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationThe classic strain pattern of ST depression and T-wave
Electrocardiographic Strain Pattern and Prediction of New-Onset Congestive Heart Failure in Hypertensive Patients The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study Peter M.
More informationIn the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension
In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial
More informationPathophysiology of Coronary Microvascular Dysfunction
Pathophysiology of Coronary Microvascular Dysfunction Cheol Woong Yu, MD, PhD Cardiology Department Division of Internal Medicine Korea University Anam Hospital. Etiologies of Chest Pain without obstructive
More informationIn hypertension, left ventricular (LV) hypertrophy (LVH) is
Heart Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism Maria Lorenza Muiesan, Massimo Salvetti, Anna Paini, Claudia Agabiti-Rosei, Cristina Monteduro, Gloria Galbassini, Eugenia
More informationLeft ventricular hypertrophy (LVH), or increased LV
Left Ventricular Mass and Geometry and the Risk of Ischemic Stroke Marco R. Di Tullio, MD; Donna R. Zwas, MD; Ralph L. Sacco, MD; Robert R. Sciacca, EngScD; Shunichi Homma, MD Background and Purpose Left
More informationReview of Cardiac Imaging Modalities in the Renal Patient. George Youssef
Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationClinic blood pressure (BP) is greater than ambulatory or
Attenuation of the White-Coat Effect by Antihypertensive Treatment and Regression of Target Organ Damage Gianfranco Parati, Luisa Ulian, Lorena Sampieri, Paolo Palatini, Alessandra Villani, Alessandro
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationCombined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve Prediction of Mortality in American Indians
Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve rediction of Mortality in American Indians The Strong Heart Study eter M. Okin, Mary J. Roman, Elisa
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationHypertension is one of the leading factors
AJH 2000;13:324 331 Arterial Wall Thickening at Different Sites and Its Association With Left Ventricular Hypertrophy in Newly Diagnosed Essential Hypertension Gaetano Vaudo, Giuseppe Schillaci, Franco
More informationCirculation. 2009;119: ; originally published online March 30, 2009; doi: /CIRCULATIONAHA
Prognostic Value of Changes in the Electrocardiographic Strain Pattern During Antihypertensive Treatment: The Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE) Peter M. Okin, Lasse
More informationRegression of left ventricular hypertrophy: lessons from clinical trials
Page 1 of 8 Systematic s Regression of left ventricular hypertrophy: lessons from clinical trials P Pokharel 1, JN Bella 1,2 * Abstract Introduction Hypertension is an epidemic that affects more than 1
More informationPRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING M-MODE ECHOCARDIOGRAPHY
Malaysian Journal of Medical Sciences, Vol. 9, No. 1, January 22 (28-33) ORIGINAL ARTICLE PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING
More informationHeart Failure with Preserved Ejection Fraction: Mechanisms and Management
Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationAge-related changes in cardiovascular system. Dr. Rehab Gwada
Age-related changes in cardiovascular system Dr. Rehab Gwada Objectives explain the main structural and functional changes in cardiovascular system associated with normal aging Introduction aging results
More informationΥπέρταση στις γυναίκες
Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe
More informationBrachial artery hyperaemic blood flow velocity and left ventricular geometry
(2011), 1 5 & 2011 Macmillan Publishers Limited All rights reserved 0950-9240/11 www.nature.com/jhh ORIGINAL ARTICLE Brachial artery hyperaemic blood flow velocity and left ventricular geometry SJ Järhult,
More informationCONGESTIVE HEART FAILURE IN PATIENTS WITH SYSTEMIC HYPERTENSION: A RETROSPECTIVE ANALYSIS WITH GATED BLOODPOOL SCINTIGRAPHY
CONGESTIVE HEART FAILURE IN PATIENTS WITH SYSTEMIC HYPERTENSION: A RETROSPECTIVE ANALYSIS WITH GATED BLOODPOOL SCINTIGRAPHY Abstract L. Beÿer & A.C. Otto Congestive heart failure (CHF) is a clinical syndrome
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More informationMædica - a Journal of Clinical Medicine
MAEDICA a Journal of Clinical Medicine 2013; 8(3): 285-289 Mædica - a Journal of Clinical Medicine STATE-OF-THE-ART Diastolic Heart Failure in Hypertension: Possible Preventive Benefits of Nebivolol Beyond
More informationRelations Between Cardiac and Vascular Structure in Patients With Primary and Secondary Hypertension
JACC Vol. 32, No. 4 October 1998:985 92 985 HYPERTENSION Relations Between Cardiac and Vascular Structure in Patients With Primary and Secondary Hypertension DAMIANO RIZZONI, MD, MARIA LORENZA MUIESAN,
More informationChanges in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease
...SYMPOSIUM PROCEEDINGS... Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease Based on a presentation by Joseph L. Izzo, Jr., MD Presentation Summary Changes in systolic
More informationSeminars in Cardiology, 2003, Vol. 9, No. 3 ISSN SEX-SPECIFIC ANALYSIS OF LEFT VENTRICULAR GEOMETRY IN A POPULATION STUDY IN TALLINN
ORIGINAL PAPERS SEX-SPECIFIC ANALYSIS OF LEFT VENTRICULAR GEOMETRY IN A POPULATION STUDY IN TALLINN Tatjana Shipilova 1, Igor Pshenichnikov 1,JüriKaik 1, Olga Volozh 1, Jelena Abina 1, Maie Kalev 1, Jaanus
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationAortic Root Dilatation as a Marker of Subclinical Left Ventricular Diastolic Dysfunction in Patients with Cardiovascular Risk Factors
The Journal of International Medical Research 2011; 39: 64 70 Aortic Root Dilatation as a Marker of Subclinical Left Ventricular Diastolic Dysfunction in Patients with Cardiovascular Risk Factors H MASUGATA,
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationLeft ventricular hypertrophy (LVH) carries a substantial
New Gender-Specific Partition Values for ECG Criteria of Left Ventricular Hypertrophy Recalibration Against Cardiac MRI Khaled Alfakih, Kevin Walters, Tim Jones, John Ridgway, Alistair S. Hall, Mohan Sivananthan
More informationHypertension in Aortic Valve Disease
Hypertension in Aortic Valve Disease Hanna M. Nosseir MRCP, FRCP Head of Cardiology department Galaa Military Medical Complex Aortic stenosis: Introduction Arterial hypertension and aortic stenosis are
More informationClinical Trial. Left Ventricular Wall Stress Mass Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients.
Clinical Trial Left Ventricular Wall Stress Mass Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients LIFE Study Richard B. Devereux, Casper N. Bang, Mary J. Roman, Vittorio Palmieri,
More informationDuring exercise the heart rate is 190 bpm and the stroke volume is 115 ml/beat. What is the cardiac output?
The Cardiovascular System Part III: Heart Outline of class lecture After studying part I of this chapter you should be able to: 1. Be able to calculate cardiac output (CO) be able to define heart rate
More informationDominic Y. Leung, MBBS, PhD; Melissa Leung, MBBS, PhD Department of Cardiology, Liverpool Hospital, University of New South Wales, Sydney, Australia
Original Article Heart Metab. (2017) 73:18-23 Early detection of left ventricular dysfunction in diabetes Dominic Y. Leung, MBBS, PhD; Melissa Leung, MBBS, PhD Department of Cardiology, Liverpool Hospital,
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationHeart. Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy
Heart Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy Peter M. Okin, Eva Gerdts, Sverre E. Kjeldsen, Stevo Julius, Jonathan M. Edelman,
More informationLeft Ventricular Systolic and Diastolic Function and Mass before and after Antihypertensive Treatment in Patients with Essential Hypertension
23 Left Ventricular Systolic and Diastolic Function and Mass before and after Antihypertensive Treatment in Patients with Essential Hypertension Yuji Yoshitomi, Toshio Nishikimi, Hitoshi Abe, Seiki Nagata,
More informationDr. A. Manjula, No. 7, Doctors Quarters, JLB Road, Next to Shree Guru Residency, Mysore, Karnataka, INDIA.
Original Article In hypertensive patients measurement of left ventricular mass index by echocardiography and its correlation with current electrocardiographic criteria for the diagnosis of left ventricular
More informationLeft Venticular Diastolic Dysfunction in Essential Hypertension
& Left Venticular Diastolic Dysfunction in Essential Hypertension Sevleta Avdić¹, Zulfo Mujčinović¹, Mensura Ašćerić²*, Sabrija Nukić¹, Zumreta Kušljugić³, Elnur Smajić³, Sedija Arapčić¹ 1. House of Health,
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationShould all patients with hypertension have echocardiography?
(2000) 14, 417 421 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Should all patients with hypertension have echocardiography? G de Simone 1,2,
More informationEarly Detection of Damaged Organ
Early Detection of Damaged Organ Regional Cardiovascular Center, Chungbuk National University Kyung-Kuk Hwang Contents NICE guideline 2011 - Confirm the diagnosis of HT ambulatory blood pressure monitoring
More informationDOWNLOAD PDF ABC OF HEART FAILURE
Chapter 1 : The ABCs of managing systolic heart failure: Past, present, and future Heart failure is a multisystem disorder which is characterised by abnormalities of cardiac, skeletal muscle, and renal
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationProspective Study of the Changes in Left Ventricular Mass and Geometry Patterns in Hypertensive Patients During 5 Years of Follow-up
Circ J 2005; 69: 1374 1379 Prospective Study of the Changes in Left Ventricular Mass and Geometry Patterns in Hypertensive Patients During 5 Years of Follow-up Alexandra O. Conrady, MD; Oleg G. Rudomanov,
More informationCardiovascular Diseases and Diabetes
Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular
More informationLab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide
Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationSTANDARD ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY
STANDARD ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY IN NIGERIAN HYPERTENSIVES Objectives: Left ventricular hypertrophy (LVH) is a major risk factor for cardiovascular morbidity and
More informationThe Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) Trial
Effects of Once-Daily Angiotensin-Converting Enzyme Inhibition and Calcium Channel Blockade Based Antihypertensive Treatment Regimens on Left Ventricular Hypertrophy and Diastolic Filling in Hypertension
More informationPrevalence of left ventricular hypertrophy in a hypertensive population
European Heart Journal (1996) 17, 143-149 Prevalence of left ventricular hypertrophy in a hypertensive population J. Tingleff, M. Munch, T. J. Jakobsen, C. Torp-Pedersen, M. E. Olsen, K. H. Jensen, T.
More informationMcHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #12 Understanding Preload and Afterload
McHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #12 Understanding Preload and Afterload Cardiac output (CO) represents the volume of blood that is delivered
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationE xperimental1,2 and autoptical 3 data support the hypothesis
Incremental Value of Ultrasonic Tissue Characterization (Backscatter) in the Evaluation of Left Ventricular Myocardial Structure and Mechanics in Essential Arterial Hypertension Vitantonio Di Bello, MD;
More informationLeft atrial function. Aliakbar Arvandi MD
In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial
More informationStructure and organization of blood vessels
The cardiovascular system Structure of the heart The cardiac cycle Structure and organization of blood vessels What is the cardiovascular system? The heart is a double pump heart arteries arterioles veins
More informationWhen should you treat blood pressure in the young?
ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationIntroduction. In Jeong Cho, MD, Wook Bum Pyun, MD and Gil Ja Shin, MD ABSTRACT
ORIGINAL ARTICLE DOI 10.4070 / kcj.2009.39.4.145 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology The Influence of the Left Ventricular Geometry on the Left
More informationDIASTOLIC HEART FAILURE
DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction
More informationDiabetes mellitus is an established risk factor for cardiovascular. Hypertension
Hypertension Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy The Losartan Intervention For Endpoint
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationPathology of Hypertension
2016-03-07 Pathology of Hypertension Honghe Zhang honghezhang@zju.edu.cn Tel:88208199 Department of Pathology ❶ Genetic predisposition ❷ Dietary factors ❸ Environmental factors ❹ Others Definition and
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationCARDIAC BENEFICIAL EFFECTS AND ADAPTATIONS IN ATHLETES
ARISTOTLE UNIVERSITY OF THESSALONIKI, GREECE SPORTS MEDICINE LABORATORY DIRECTOR: PROF. A. DELIGIANNIS CARDIAC BENEFICIAL EFFECTS AND ADAPTATIONS IN ATHLETES ASTERIOS DELIGIANNIS CARDIOLOGIST PROFESSOR
More informationThe incidence of transient myocardial ischemia,
AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand
More informationChapter 10 Worksheet Blood Pressure and Antithrombotic Agents
Complete the following. 1. A layer of cells lines each vessel in the vascular system. This layer is a passive barrier that keeps cells and proteins from going into tissues; it also contains substances
More informationImpact of Ventricular Geometric Pattern on Cardiac Remodeling after Myocardial Infarction
Impact of Ventricular Geometric Pattern on Cardiac Remodeling after Myocardial Infarction Elaine Farah, Daniéliso R. Fusco, Paulo R. R. Okumoto, Marcos F. Minicucci, Paula S. Azevedo, Beatriz B. Matsubara,
More informationDiastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure
Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics
More informationΗ σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις
Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Ελένη Τριανταφυλλίδη Επιμελήτρια Α Β Πανεπιστημιακή Καρδιολογική Κλινική Αττικό Νοσοκομείο
More information